Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group
详细信息 查看全文
- 作者：Anna Patrikidoua ; Julien Domonta ; Sylvie Chabaudb ; Isabelle Ray-Coquardb ; Jean-Michel Coindrec ; Binh Bui-Nguyenc ; Antoine Adenisd ; Maria Riose ; Franç ; ois Bertuccif ; Florence Duffaudg ; Christine Chevreauh ; Didier Cupissoli ; David Pé ; rolb ; Jean-Franç ; ois Emilej ; Jean-Yves Blayk ; Axel Le Cesnea ; Axel.LECESNE@gustaveroussy.fr" class="auth_mail" title="E-mail the corresponding author ; for the French Sarcoma Group
- 关键词：GIST ; imatinib mesylate ; mutational status ; prognostic factors ; outcome analysis
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：52
- 期：Complete
- 页码：173-180
- 全文大小：1147 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
KIT exon 11 mutation is an independent prognostic factor for PFS and OS in GIST patients.
- class="label">•
Clinico-biological factors (gender, PS, tumour size, lymphocyte & neutrophil count) are also significant.
- class="label">•
Subsets of exon 11 mutations have significantly different response patterns and PFS in GIST patients.